Patienter med typ 1-diabetes har ökad risk för hjärtsvikt, jämfört med övriga befolkningen. Höga blodsockernivåer och tidigt insjuknande är viktiga riskfaktorer.
De slutsatserna dras av forskare vid bland annat Sahlgrenska akademin i en studie som nyligen publicerades i tidskriften Lancet, enligt referat i Dagens Medicin av Katrin Trysell.
Patienter med typ 1-diabetiker löper drygt 10 gånger högre risk än befolkningen i allmänhet att drabbas av hjärtsvikt. Detta är viktig kunskap vid omhändertagandet av patienter med ökad risk för kardiovaskulär sjukdom.
Resultaten i studien visar att risken för hjärtsvikt ökar fyrfaldigt om patientens metabola kontrolol, HbA1c, ligger långt över de rekommenderade värdena.
Forskargruppen följde 20 985 vuxna med diabetes under i median nio år. Under den tiden fick 635 av patienterna diagnosen hjärtsvikt, enligt Katrin Trysell.
Marcus Lind, specialistläkare i endokrinologi vid NU-sjukvården och medicine doktor vid Sahlgrenska akademin, är en av dem som står bakom studien, tillsammans med Nationella Diabetes Registret.
Enligt forskarna tyder resultaten på att en förbättrad metabol kontroll skulle kunna förhindra insjuknande i hjärtsvikt hos typ 1-diabetiker.
Annika Rosengren, överläkare och professor vid Sahlgrenska sjukhuset/Östra, och ytterligare en av forskarna bakom studien, anser att de även gör frågan om riktad screening med ultraljud av hjärtat för hjärtsvikt än mer aktuell.
____
Abstract
he Lancet, Volume 378, Issue 9786, Pages 140 – 146, 9 July 2011
Glycaemic control and incidence of heart failure in 20 985 patients with type 1 diabetes: an observational study
Dr Marcus Lind MD, Ioannis Bounias MD c, Marita Olsson PhD d, Soffia Gudbjörnsdottir MD e, Ann-Marie Svensson RN f, Prof Annika Rosengren MD
Summary
Background
Poor glycaemic control is associated with microvascular and macrovascular complications in type 1 diabetes, but whether glycaemic control is associated with heart failure in such patients is not known. We aimed to assess this association in a large cohort of patients with type 1 diabetes identified from the Swedish national diabetes registry.
Methods
We identified all patients (aged ≥18 years) with type 1 diabetes and no known heart failure who were registered in the national diabetes registry between January, 1998, and December, 2003. These patients were followed up until hospital admission for heart failure, death, or end of follow-up on Dec 31, 2009. We calculated incidence categorised by glycated haemoglobin A1c (HbA1c) values, and we assessed the association between patients’ characteristics, including HbA1c, and heart failure.
Findings
In a cohort of 20 985 patients with mean age of 38·6 years (SD 13·3) at baseline, 635 patients (3%) were admitted to hospital with a primary or secondary diagnosis of heart failure during a median follow-up of 9·0 years (IQR 7·3—11·0), with an incidence of 3·38 events per 1000 patient-years (95% CI 3·12—3·65). Incidence increased monotonically with HbA1c, with a range of 1·42—5·20 per 1000 patient-years between patients in the lowest (<6·5%) and highest (≥10·5%) categories of HbA1c. In a Cox regression analysis, with adjustment for age, sex, duration of diabetes, cardiovascular risk factors, and baseline or intervening acute myocardial infarction and other comorbidities, the hazard ratio for development of heart failure was 3·98 (95% CI 2·23—7·14) in patients with HbA1c of 10·5% or higher compared with a reference group of patients with HbA1c of less than 6·5%. Risk of heart failure increased with age and duration of diabetes. Other modifiable factors associated with increased risk of heart failure were smoking, high systolic blood pressure, and raised body-mass index. In a subgroup of 18 281 patients (87%) with data for blood lipids, higher HDL cholesterol was associated with lower risk of heart failure, but there was no association with LDL cholesterol.
Interpretation
The positive association between HbA1c and risk of heart failure in fairly young patients with type 1 diabetes indicates a potential for prevention of heart failure with improved glycaemic control.
Nyhetsinfo
www red DiabetologNytt
Publicerad: |2011-08-25|
